Eisai Receives Approval to Market Pariet Triple Formulation Packs Rabecure 400
and 800 and Rabefine, for Primary and Secondary H. Pylori Eradication
Respectively, in Japan
Tokyo, Aug 21, 2013 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo,
President & CEO: Haruo Naito, "Eisai") announced today that it
has received marketing authorization from Japan's Ministry of Health,
Labour and Welfare for two types of triple formulation packs (combination
packs) that contain its proton pump inhibitor Pariet (rabeprazole sodium) for
Helicobacter pylori eradication.
The authorization approves Rabecure Pack 400 and Rabecure Pack 800, which
package together individual blister sheets each containing a daily triple
formulation dose of Pariet, amoxicillin hydrate and clarithromycin for primary
H. pylori eradication, and Rabefine Pack, which similarly packages together
individual blister sheets each containing a daily triple formulation dose of
Pariet, amoxicillin hydrate and metronidazole for secondary H. pylori
In H. pylori eradication triple therapy with Pariet and two antimicrobial
agents, successful eradication significantly depends on whether the patient
properly adheres to the prescribed treatment regimen. Taking the incorrect dose
or missing doses altogether can not only lead to reduced eradication rates but
also to bacterial resistance and increased side effects. Both the primary and
secondary eradication combination packs contain daily triple formulation doses
of Pariet and two antimicrobial agents packaged in individual blister sheets
and as such are expected to help ensure that H. pylori eradication therapy is
carried out more appropriately and with greater certainty, improve patient drug
compliance, and offer increased convenience in a medical setting.
Eisai believes that its Rabecure and Rabefine combination packs will further
promote the proper use of agents used in H. pylori eradication and further
contribute to increasing the benefits provided to patients with diseases
associated with H. pylori.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care
(hhc) company that discovers, develops and markets products throughout the
world. Eisai focuses its efforts in three therapeutic areas: integrative
neuroscience, including neurology and psychiatric medicines; integrative
oncology, which encompasses oncotherapy and supportive-care treatments; and
vascular/immunological reaction. Through a global network of research
facilities, manufacturing sites and marketing subsidiaries, Eisai actively
participates in all aspects of the worldwide healthcare system. For more
information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department,
Eisai Co., Ltd.
Copyright 2013 JCN Newswire. All rights reserved. www.japancorp.net
Provider ID: 00027281
Press spacebar to pause and continue. Press esc to stop.